

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/092,954	03/06/2002	David D. Konieczynski	022719-0023	7357
21125	7590 06/01/2005		EXAMINER	
NUTTER MCCLENNEN & FISH LLP			MAIORINO, ROZ	
WORLD TRADE CENTER WEST 155 SEAPORT BOULEVARD			ART UNIT	PAPER NUMBER
BOSTON, MA 02210-2604			3763	

DATE MAILED: 06/01/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

SOPPHMA	ital	SP			
•	Application No.	Applicant(s)			
	10/092,954	KONIECZYNSKI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Roz Maiorino	3763			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w.  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
<ul> <li>1) Responsive to communication(s) filed on 14 February 2005.</li> <li>2a) This action is FINAL. 2b) This action is non-final.</li> <li>3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.</li> </ul>					
Disposition of Claims					
4)	<u>26 and 27</u> is/are withdrawn from o	consideration.			
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the I drawing(s) be held in abeyance. See ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:				

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

1. Claims 1, 3, 10-11, 15, 17, 28-39 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent NO.5569186 to Lord et al.

Lord teaches an infusion pump including a fluid outlet; a fluid delivery pathway effective for extending from the fluid outlet to a discharge portion positionable at a target tissue site; and a controlled release drug assembly, the drug assembly being configured

Application/Control Number: 10/092,954 Page 3

Art Unit: 3763

for controllably releasing drug material, and communicating with the fluid delivery pathway such that the drug material is released into the fluid delivery pathway, wherein the pump assembly is effective to deliver a carrier fluid to the fluid outlet such that the drug material released into the fluid pathway discharges at the discharge portion to treat the target tissue site.

2. Claims 1, 3, 7-8, 10-11, 14-17, 19-20, 22, 25, 28-40 rejected under 35 U.S.C. 102(e) as being anticipated by US Pub NO. 25004/0034332 to Uhland.

Uhland teaches an infusion pump including a fluid outlet; a fluid delivery pathway effective for extending from the fluid outlet to a discharge portion positionable at a target tissue site; and a controlled release drug assembly, the drug assembly being configured for controllably releasing drug material, and communicating with the fluid delivery pathway such that the drug material is released into the fluid delivery pathway, wherein the pump assembly is effective to deliver a carrier fluid to the fluid outlet such that the drug material released into the fluid pathway discharges at the discharge portion to treat the target tissue site. Drug assembly is a microchip; the system also comprises of biosensors.

#### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/092,954

Art Unit: 3763

Claims 7-8, 14, 19, 20, 22, 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent NO.5569186 to Lord et al as applied to claim 1 above, and further in view of US Patent NO.5797898 to Santini et al..

As mentioned above Lord teaches the invention except for a microchip.

Santini teaches a use of microchip in drug delivery.

Therefore it would have been obvious to one having ordinarily skill in the art at the time the invention was made to have added a microchip for the reservoir because as Santini teaches a microchip allows for a wide variety of delivery rate as well as for storing different type of drugs.

### Response to Arguments

3. Applicant's arguments with respect to claims 1, 3, 7-8, 10-11, 14-17, 19-20, 22, 25, 28-40 have been considered but are moot in view of the new ground(s) of rejection.

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Application/Control Number: 10/092,954 Page 5

Art Unit: 3763

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roz Maiorino whose telephone number is 571-272-4960. The examiner can normally be reached on 9am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4377. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**RM** 

NICHOLAS D. LUCCHESI SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700